Oral
Dasatinib
Sprycel
Binds both active & inactive conformation of Bcr-Abl kinase, resulting in reduced resistance
- Mechanism of Action
- Inhibits the Bcr-Abl tyrosine kinase as well as the stem cell receptor factor (cKIT) and several other receptor tyrosine kinases.
Clinical Use
- Indications
- Philadelphia chromosome positive chronic myeloid leukaemia in the chronic phase or with resistance or intolerance to imatinib
- Philadelphia chromosome positive acute lymphoblastic leukaemia
- Adverse Effects
- Rash
- Fatigue
- Oedema
- Nausea / vomiting / diarrhoea
- Muscle cramping
- Peripheral neuropathy
- LFT derangement
- Myelosuppression - anaemia, neutropaenia, thrombocytopaenia
- Respiratory - pleural effusions, pulmonary hypertension
Want more info like this?
- Your electronic clinical medicine handbook
- Guides to help pass your exams
- Tools every medical student needs
- Quick diagrams to have the answers, fast
- Quizzes to test your knowledge
Explore